Therapeutic hotline: Primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma coexisting with myelodysplastic syndrome transforming into chronic myelomonocytic leukemia successfully treated with cyclophosphamide.
Cutaneous T cell lymphomas other than mycosis fungoides, Sezary syndrome, and primary cutaneous CD30+ lymphoproliferations constitute less than 10% of all cutaneous T cell lymphomas. Primary cutaneous small/medium CD4+ T cell lymphoma is a member of this third group of cutaneous lymphomas, separated out as provisional entity in the World Health Organization classification - European Organization for Research and Treatment of Cancer (WHO-EORTC) classification. It still awaits development of more precise diagnostic criteria and optimal therapy. We report a case of primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma accompanied with myelodysplastic syndrome successfully treated with cyclophosphamide. It seems that cyclophosphamide as a single-agent chemotherapy in patients with disseminated lesions might be safe and quite effective therapeutic option.
Chair and Department of Dermatology, Venereology and Pediatric Dermatology Medical University of Lublin, Prague, Czech Republic. bartekwawrzycki@o2.pl
Bartłomiej
B
Wawrzycki
Grazyna
G
Chodorowska
Aldona
A
Pietrzak
Iwona
I
Jazienicka
Danuta
D
Skomra
Małgorzata
M
Kowal
Ewa
E
Dybiec
Jana
J
Hercogova
D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001706:Biopsy; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D016410:Lymphoma, T-Cell, Cutaneous / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D012867:Skin / Q000276:immunology / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide